Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Biovitrum
Woman and Man Max 99 years
Swedish Orphan Biovitrum AB
Update Il y a 4 ans
Taste and palatability of Orfadin suspension
To determine the acceptability of the suspension in the pediatric population.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biovitrum AB
Update Il y a 4 ans
A double-blind, placebo-controlled, randomized, parallel-group study evaluating the efficacy and tolerability of oral BVT.115959, a novel A2A agonist, versus placebo in the treatment of diabetic neuropathic pain
To compare the analgesic properties of BVT.115959 in subjects with diabetic neuropathic pain against placebo following 4 weeks’ treatment.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biovitrum AB
Update Il y a 4 ans
An open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency
To assess the effect of rhBSSL on the coefficient of fat absorption in patients with cystic fibrosis and pancreatic insufficiency, following administration of a fixed daily dose of rhBSSL.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Swedish Orphan Biovitrum AB (Publ)
Update Il y a 4 ans
An open-label, non-randomized, sequential, multicenter study to evaluate the pharmacokinetics, efficacy and safety of once daily dosing compared to twice daily dosing of Orfadin in patients diagnosed with hereditary tyrosinemia type 1
To evaluate the steady-state exposure to nitisinone during once and twice daily dosing of Orfadin
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biovitrum AB
Update Il y a 4 ans
A prospective, randomised, double-blind crossover study comparing 0.15 g/L rhBSSL added to infant formula versus placebo during one week of treatment in preterm infants born before week 32 of gestational age
The primary objective of this study is to compare the fat absorption (coefficient of fat absorption) in preterm infants following treatment with rhBSSL to that with placebo when administered in infant...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Swedish Orphan Biovitrum AB (Publ)
Update Il y a 4 ans
A phase 3 clinical study investigating the effects of rhBSSL (an enzyme to help digestion of fat) added to pasteurized breast milk or formula in babies born prematurely
The primary objective of this study is to demonstrate that rhBSSL improves growth in preterm infants as compared with placebo when administered in infant formula or PBM.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Swedish Orphan Biovitrum AB (Publ)
Update Il y a 4 ans
To determine a safe and tolerable dose of palifermin in pediatric subjects of different age groups when administered once daily for 3 consecutive days before and 3 consecutive days after a myeloablative chemo-radiotherapy conditioning regimen with allogeneic hematopoietic stem cell transplant (HSCT)
To determine a safe and tolerable dose of palifermin in pediatric subjects of different age groups when administered once daily for 3 consecutive days before and 3 consecutive days after a myeloablati...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Biovitrum AB
Update Il y a 4 ans
A prospective, randomised, double-blind crossover study comparing 0.15 g/L rhBSSL added to pasteurized breast milk versus placebo during one week of treatment in preterm infants born before week 32 of gestational age
The primary objective of this study is to compare the fat absorption (coefficient of fat absorption) in preterm infants following treatment with rhBSSL to that with placebo when administered in pasteu...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years and 70 years
Biovitrum
Update Il y a 4 ans
Biovitrum 20050219 : Essai de phase 3, randomisé, en double aveugle, évaluant l’efficacité de la palifermine dans la réduction de la mycose orale sévère chez des patients ayant un myélome multiple, traité par melphalan à haute dose suivi par une greffe autologue de cellules souches hématopoïétiques périphériques. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Cet essai a pour objectif l’évaluation de l’efficacité et des effets de la palifermine sur l’incidence de la mycose orale chez des patients atteints d’un myélome multiple traité par melphalan suivi pa...
Country
France
organs
Myélomes
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Biovitrum AB
Update Il y a 4 ans
A 4-week, double-masked, parallel-group, randomized , multicenter, proof of concept study comparing the efficacy and safety of two dose levels of BVT.28949 with placebo in patients with ocular hypertension or open angle glaucoma
The primary objective is to compare mean reduction in diurnal IOP between each of the two groups receiving BVT.28949 (2 mg/mL, 7 mg/mL) and the placebo group after 4 weeks of treatment.
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
Next